Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

12 Feb 2016
Change (% chg)

$-0.06 (-1.47%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PGNX.OQ


Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in... (more)


Beta: 2.20
Market Cap(Mil.): $279.92
Shares Outstanding(Mil.): 69.81
Dividend: --
Yield (%): --


  PGNX.OQ Industry Sector
P/E (TTM): -- 60.71 37.45
EPS (TTM): -0.63 -- --
ROI: -30.14 6.65 14.17
ROE: -37.98 8.86 14.92
Search Stocks

BRIEF-Exini Diagnostics applies for voluntary removal of shares from trading on First North

* Said on Monday at the request of Progenics Pharmaceuticals, Inc, the board of Exini has resolved to apply for voluntary removal of the shares from trading on First North

17 Nov 2015

BRIEF-Progenics Pharmaceuticals makes tender offer for in Exini Diagnostics

* Progenics Pharmaceuticals Inc has on Oct 13 announced offer to tender all of shares in Exini for a consideration of 3.15 Swedish crowns per share

13 Oct 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : S&P Capital IQ Quantitative Report
Provider : Reuters Investment Profile
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks